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Objectives: Reactive oxygen species (ROS) are associated with aging. Astaxanthin is a 
strong antioxidant and has been reported to prevent various ROS-induced diseases. In 
the current study, we investigated the effect of astaxanthin on age-associated 
histological and mRNA changes of vocal folds. 
Study design: Prospective animal experiment with control. 
Methods: Six-month-old Sprague-Dawley rats were fed on a normal powder diet with 
0.01% (w/w) astaxanthin (aged Ast-treated group) or without astaxanthin (aged 
sham-treated group). After 12 months of feeding, the larynges were harvested for 
histology, immunohistochemical detection of 4-hydroxy-2-nonenal (4-HNE) and 
quantitative real-time PCR for basic fibroblast growth factor (bFGF) and hepatocyte 
growth factor (HGF). Thirteen-week-old rats were used as a young control group (young 
group). 
Results: The expression of 4-HNE, an oxidative stress marker, significantly increased in 
the two aged groups compared to the young group. Histological examination showed 
that the deposition of hyaluronic acid in the lamina propria was significantly reduced in 
the aged sham-treated group compared to the young group, but no significant difference 
was observed between the aged Ast-treated group and the young group. There were no 
significant differences in the mRNA expression of bFGF and HGF between the aged 
Ast-treated group and the young group, although the expression of these genes was 
significantly reduced in the aged sham-treated group as compared to the young group. 
Conclusions: These results suggest that astaxanthin has the potential to attenuate 
age-associated changes of vocal folds. 
Key Words: astaxanthin, age-associated changes, vocal folds, reactive oxygen species 
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Many hypotheses of aging have been proposed including the reactive oxygen 
species/mitochondria theory, the DNA/genetic theory, and the telomerase theory, 1, 2 
although none of these theories completely accounts for aging. Reactive oxygen species 
(ROS) are candidates for aging factors. ROS are normal by-products of cellular 
metabolism. Under basal conditions, 3-5% of the total oxygen consumed by 
mitochondria is converted to ROS. 3, 4 Therefore, mitochondria are thought to be exposed 
to ROS during a lifetime. The accumulation of ROS damage during aging oxidizes lipids, 
consequently modifying membrane lipid composition and reducing its fluidity. Finally, 
ROS increase mitochondrial membrane rigidity and reduce efficiency of mitochondrial 
oxidative phosphorylation, resulting in cell apoptosis.5, 6 Thus, regulation of ROS may 
be a target for anti-aging therapy or treatment of age-associated diseases. Catalase is 
an anti-oxidant enzyme and catalyzes the reduction of hydrogen peroxide (H2O2) before 
H2O2 is converted to hydroxyl radicals, which are highly aggressive. Schriner et al. 
reported that overexpression of catalase in mitochondria leads to a reduction of 
oxidative stress and an extension of lifespan.7 In addition, age-associated diseases 
including cardiovascular diseases and diabetes have been reported to be improved by 
antioxidant agents.8, 9 
The age-associated changes of human voices include harshness, reduced 
loudness, increased breathiness, and unsteadiness,10 which can lead to an impairment 
in the quality of life. These age-associated changes result from several factors including 
the loss of respiratory function, laryngeal muscle atrophy, neurological changes, and 
microstructural changes of the vocal fold mucosa. Previous studies investigated 
age-associated histological changes in the lamina propria (LP) of the vocal folds. It was 
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reported that elastic fibers and hyaluronic acid (HA) were reduced and, conversely, 
collagenous fibers were increased with aging.11-15 Chen and Thibeault investigated gene 
expression of human vocal fold fibroblasts from various aged donors and showed that 
gene expression levels for collagen I, collagen VI, procollagen I and elastin decreased 
with increasing age of the donor.16 These age-associated changes of gene expression may 
result in age-associated histological changes of vocal folds. 
Astaxanthin is a xanthophyll carotenoid and occurs naturally in living 
organisms, particularly in the marine environment.17, 18 Astaxanthin has a strong 
antioxidant effect as a potent quencher of singlet oxygen and many studies have shown 
favorable effects of astaxanthin on the regulation of oxidative stress.8, 18-20 For example, 
Gross et al. demonstrated that the administration of astaxanthin decreased myocardial 
infarct size through reducing ischemia-reperfusion injury caused by ROS.20 Hama et al. 
reported that topical administration of astaxanthin to the skin prevented damage 
induced through oxidative stress by ultraviolet irradiation.21 Regarding the vocal folds, 
we demonstrated previously that astaxanthin treatment significantly reduced oxidative 
stress in the LP during the early phases of vocal fold wound healing and significantly 
reduced tissue contraction with favorable deposition of HA in the LP.22 
Considering the ROS aging theory, we hypothesized that a reduction of 
oxidative stress in the cells of the vocal fold, such as fibroblasts, may lead to the 
attenuation of down-regulation of gene expression involved in ECM organization and 
prevent age-associated changes of vocal folds. To address this hypothesis, in the current 
study, we investigated the effect of astaxanthin on age-associated histological changes of 
vocal folds. After feeding rats on a diet containing astaxanthin for 12 months, we 
examined the histology and immunohistochemistry of 4-hydroxy-2-nonenal (4-HNE), an 
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oxidative stress marker. In addition, to investigate the effect of astaxanthin on LP cells, 







Materials and methods  
Animals and drug treatment 
The astaxanthin material, composed of 5.0% or 2.0% (w/w) of astaxanthin was 
extracted from Haematococcus pluvialis, which was supplied by Fuji Chemical Industry 
Co. Ltd. (Toyama, Japan). 
Thirty Sprague-Dawley rats were used in this study. Ten thirteen-month-old 
rats were used to investigate the transmission into vocal fold mucosa of astaxanthin, 
which was administered orally. After 100 mg/day/kg astaxanthin was administered by 
oral gavage daily for seven days, rats were humanely euthanized with an intracardiac 
injection of sodium pentobarbital (200 mg/kg) after inhalative sedation with diethyl 
ether. And then whole larynges were harvested for high-performance liquid 
chromatography (HPLC). 
Twenty six-month-old male rats were used to investigate the age-associated 
changes of vocal fold. Ten rats were fed a normal powder diet supplemented with 0.01% 
(w/w) astaxanthin (aged Ast-treated group), while the other ten rats were fed a normal 
powder diet without astaxanthin (aged sham-treated group). The astaxanthin material, 
composed of 2.0% (w/w) astaxanthin, was mixed with the powder diet. After 12 months 
of feeding, the rats were humanely euthanized as described above. Whole larynges were 
harvested from each animal and then the larynges were split into the left and right 
sides. The left sides of larynges were used for histological and immunohistochemical 
examination, while the right sides were used for real-time PCR.  
Since Sprague-Dawley rats live to be approximately 24 months, 
eighteen-month-old rats were selected in the current study to represent aged animals. 
Thirteen-week-old rats were used as a young control group (young group). 
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All experimental protocols were approved by the Animal Research Committee 
of the Kyoto University Graduate School of Medicine. Animal care was provided by the 
Institute of Laboratory Animals of Kyoto University. 
 
High-performance liquid chromatography (HPLC) 
In order to examine transmission of astaxanthin into the vocal fold, the whole 
larynges of ten rats were harvested; the epithelium and lamina propria of the vocal fold 
were dissected away from the larynx under the microscope. The dissected specimens 
were frozen quickly in liquid nitrogen and stored at -80°C until use. Since the vocal folds 
of rats are small, twenty vocal fold mucosa from the ten rats were put all together into 
one sample. Astaxanthin was extracted from the vocal fold mucosa with 2 ml acetone at 
room temperature. The extract solution was concentrated by evaporating. The residue 
was dissolved in 50 µl of acetone/hexane (2:8) solution and subjected to HPLC analysis. 
HPLC was performed on a Hitachi (Tokyo, Japan) L-6200 intelligent pump with a 
Hitachi L-4250 UV–VIS detector set at 470 nm absorbance. Astaxanthin was detected 
by HPLC on a Cosmosil 5SL-II 250×4.6 mm i.d., column (Nacalai Tesque, Kyoto, Japan) 
with acetone/hexane as a solvent at a flow rate of 1.0 ml/min at room temperature. 
Standard astaxanthin was provided by DSM Nutrition Japan (Tokyo, Japan). 
 
Immunohistochemical and histological examinations 
Age-related histological changes of the vocal fold were examined in the rats 
that were fed with or without astaxanthin. The harvested left sides of the larynges 
were immersed in 4% paraformaldehyde for 24 hours then in 30% sucrose for 24 hours. 
The tissues were then soaked in embedding medium (Optimum Cutting Temperature 
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Compound; Tissue-Tek Inc., Kyoto, Japan) and frozen quickly with liquid nitrogen. Ten 
µm-thick cryostat sections (Leica, CM 1850 Kryostat; Leica Instruments GmbH, 
Nussloch, Germany) of larynges were made vertical to the glottis (coronal sections), air 
dried, and stored at -80°C until use.  
For immunohistochemical examination, specimens were incubated overnight 
at 4°C with a rabbit anti-4-HNE antibody (Alpha Diagnostic International Co., San 
Antonio, TX, USA, 1:500) after blocking. Samples were washed, then incubated 
overnight at 4°C with Alexa-Fluor 488 goat anti-rabbit IgG (Invitrogen, France, 1:500). 
4’, 6’-diamidino-2-phenylindole dihydrochloride (DAPI) was used to stain cell nuclei in 
each specimen. Omission of the primary antibody served as a negative control. Images 
were captured with a Biorevo BZ-9000 microscope (Keyence Co., Osaka, Japan). 
Immunohistochemical staining of all the samples occurred simultaneously and all 
images were captured at 10X magnification with the same exposure and shutter speed. 
For histological examination, Alcian blue staining and a hyaluronidase digestion 
technique were performed to identify HA. In addition, Elastica van Gieson staining 
was performed to identify collagen. Images were captured at 10X magnification with a 
Biorevo BZ-9000 microscope. 
Biorevo BZ-H1C and BZ-H1M software (Keyence Co.) was used to measure the 
4-HNE-immunopositive areas in immunohistochemistry and blue-stained areas in 
Alcian blue staining. This software automatically measures the area of a designated 
color in a section. The threshold of 4-HNE-immunopositive or blue-stained color was 
determined by the examiner and saved by the computer. Under the same color criteria, 
the 4-HNE-immunopositive and blue-stained areas were measured in the entire 
lamina propria of three different regions in the vocal fold: anterior, middle, and 
11 
 
posterior portions. These areas were then totaled (S1) for each vocal fold. In addition, 
the areas of the lamina propria were measured in all the regions and totaled (S2) for 
each vocal fold. The ratio of 4-HNE-immunopositive area, or blue-stained area, was 
determined by dividing S1 by S2 for each vocal fold. The ratio of HA-stained area in the 
LP was determined by subtracting the ratio of the blue-stained area of the section with 
hyaluronidase digestion from that of an adjacent section without digestion. These 
assessments were performed in a blinded fashion in which the examiners were not 
informed of the experimental group to which each section belonged. 
Real-time PCR 
In order to examine gene expression in the vocal folds, the harvested right 
sides of larynges were immediately immersed in RNAlater (QIAGEN, Valencia, CA, 
USA), incubated overnight, and then the epithelium and LP of the vocal fold were 
dissected away from the larynx under the microscope. The dissected specimens were 
frozen quickly in liquid nitrogen and stored at -80°C until use. The RNeasy Mini Kit 
(QIAGEN) was used to isolate total RNA following the manufacturer’s protocol. The 
quantity and quality of the RNA were evaluated by measuring the A260/280 ratio of 
the RNA samples. Reverse transcription was performed using a High Capacity cDNA 
Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA) using the 
manufacturer’s recommended reaction protocol. Reactions were performed with a 
Veriti Thermal Cycler (Applied Biosystems) using the following parameters: 25°C for 
10 minutes, 37°C for 120 minutes, 85°C for 5 minutes, and 4°C for 5 minutes. 
We examined the mRNA expression of hyaluronic acid synthase (HAS)-1, 
HAS-2, and HAS-3, procollagen types I and III, matrix metallopeptidase (MMP)-1a, 
MMP-8, basic fibroblast growth factor (bFGF), hepatocyte growth factor (HGF), and 
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beta 2-microglobulin (as a endogenous control). Rat-specific primers were used. The 
primers were synthesized by Hokkaido System Science Co, Japan and are displayed in 
Table 1. Real-time PCR was performed in a final volume of 20 µL according to the 
manufacturer’s protocol. The reaction mix was comprised of template cDNA, 10 µL of 
Power SYBR Green Master Mix (Applied Biosystems), 0.25 µmol/L final concentration 
of each primer, and ribonuclease-free water. The amplification was performed under 
the following conditions: 95°C for 10 minutes, and 40 cycles of denaturing at 95°C for 
15 seconds and annealing at 60°C for 1 minute. Fluorescence was detected with 
StepOnePlus (Applied Biosystems). Standard curves were used to determine the 
relative ratio of gene expression for each gene. Target gene ratios were normalized 
using the endogenous control gene (beta 2-microglobulin).  
 
Statistical Analysis 
One-way factorial analysis of variance (ANOVA) followed by a Tukey-Kramer 
post hoc test was performed to investigate the differences of the mRNA expression of 
HAS-1, HAS-3, MMP-1a, MMP-8, and HGF between the three groups. A 
Kruskal-Wallis test followed by a Steel-Dwass post-hoc test was performed to 
investigate the difference of the expression areas of 4-HNE, HA ratio, and the mRNA 
expression of the other genes because the data failed tests for homogeneity of variance. 







Transmission to vocal folds of astaxanthin 
 HPLC chromatogram of the extraction from the vocal fold mucosa showed the 
peak corresponding to astaxanthin (Fig. 1). Although this peak was so small that 
astaxanthin content could not be quantified, this suggests the existence of astaxanthin 
in the vocal fold mucosa. 
Survival of aged rats 
Seven of ten rats survived in the aged Ast-treated group, while five of ten 
survived in the aged sham-treated group.  
Expression of 4-hydroxy-2-nonenal (4-HNE) 
 The expression of 4-HNE increased with aging in the LP of the vocal folds (Fig. 
2). Image analysis showed a significant increase of 4-HNE-immunopositive areas in 
both aged groups as compared to the young group. There were no significant differences 
in the 4-HNE-immunopositive area between the aged sham-treated group and the 
Ast-treated group. 
Histological examination 
Alcian blue staining and a hyaluronidase digestion technique showed the 
deposition of HA (Fig. 3). Image analysis showed that the deposition of HA in the LP 
was significantly reduced in the aged sham-treated group compared to the young group. 
No significant differences were observed between the aged Ast-treated group and the 
young group (p=0.21), or between the two aged groups. Elastica van Gieson staining 
showed excessive deposition of disorganized collagen in the LP in both aged groups. 
Real-time PCR 
The mRNA expression ratios of several extracellular matrix genes were 
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examined (Fig. 4). The two aged groups showed significantly down-regulated mRNA 
expression of HAS-1, HAS-2, HAS-3, procollagen types I and III, MMP-1a, and MMP-8 
as compared to the young group. Regarding the expression of growth factor genes, there 
were no significant differences in the expression of bFGF (p=0.36) or HGF (p=0.30) 
between the aged Ast-treated group and the young group, although the aged 
sham-treated group showed significantly down-regulated expression of these genes as 
compared to the young group (Fig. 5). No significant differences were observed in the 




In the current study, the age-associated histological change of vocal folds was 
consistent with previous studies.13-15 The deposition of HA in the LP was significantly 
reduced in the aged sham-treated group compared to the young group. Excessive 
deposition of disorganized collagen was observed in the LP of the aged vocal folds. By 
immunohistochemical examination, the expression of 4-HNE increased significantly 
with aging, which suggests an age-associated accumulation of oxidative stress in the 
vocal folds. In addition, the mRNA expression level of genes involved in ECM 
organization of the LP decreased significantly with aging.  
Unfortunately, the current preliminary study showed no significant differences 
in any of the examinations between the two aged groups. This study has some 
limitations. Possible reasons are a sampling size and bias. Although twenty rats (ten 
per each group) were used at the beginning of the study, just twelve rats survived and 
were analyzed at the endpoint of this study. And the animals that survived may be more 
tolerant of oxidative stress, which may lead to sampling bias. The small sample size and 
possible sampling bias may have affected the result analysis.  
The other limitation of the current study is a lack of knowledge about what 
dose is required to be effective for the vocal fold. Astaxanthin administered orally can 
transmit into vocal fold mucosa, which is suggested by the current HPLC study. Our 
previous study showed that 100 mg/kg/day astaxanthin administered by oral gavage for 
six days could influence the vocal fold.22 However, it is difficult to continue the 
administration by oral gavage for a long time. Therefore, we decided to feed the rats a 
diet containing 0.01 % (w/w) astaxanthin by referencing a previous study.23 Nakano et 
al. fed seven-week-old rats a diet containing 0.01 % (w/w) astaxanthin and another 
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antioxidant for 12 weeks and their examinations after feeding showed a significant 
reduction in the levels of various oxidative stress markers. However, the dose 
administered in the current study may not be enough. The administration of an 
increased amount of astaxanthin, or in combination with other antioxidants, might 
reveal a better outcome. 
On the other hand, no significant difference was observed in the deposition of 
HA in the LP between the aged Ast-treated group and the young group, although the 
aged sham-treated group showed a significant reduction of HA compared to the young 
group. It is sure that the small sample size might influence the result analysis, but this 
suggests that the administration of astaxanthin might contribute to the prevention of 
an age-associated reduction of HA. Since HA is regarded as an essential molecule for 
ideal viscoelasticity of the vocal folds, the preservation of HA is thought to contribute to 
maintenance of favorable mucosal vibration. In addition, there were no significant 
differences in the mRNA expression of bFGF or HGF between the aged Ast-treated 
group and the young group, although the aged sham-treated group showed significantly 
down-regulated expression of these genes as compared to the young group. Growth 
factors such as bFGF and HGF have been reported to have the potential to improve 
age-associated change of vocal folds.24-27 Moreover, a clinical trial was performed in 
Japan using bFGF for aged vocal folds, which demonstrated bFGF was effective for aged 
vocal folds.28 In our previous study,22 astaxanthin administration significantly 
increased the expression of bFGF during wound healing. This previous study is 
consistent with the current results. Our current results might also suggest that 
continuous administration of astaxanthin leads to the prevention of age-associated 
changes in voices through preserving the deposition of HA in the LP and maintaining 
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expression of growth factors such as HGF and bFGF. 




This preliminary study demonstrated that a continuous administration of 
astaxanthin might attenuate the age-associated reduction of the deposition of HA in the 
LP and expression of HGF and bFGF. This suggests that astaxanthin has the potential 




This study was supported by the Advanced Research for Medical Products 





1. Bonawitz ND, Shadel GS. Rethinking the mitochondrial theory of aging: the role of 
mitochondrial gene expression in lifespan determination. Cell Cycle. 
2007;6:1574-1578.  
2. Gavrilov LA, Gavrilova NS. The quest for a general theory of aging and longevity. 
Sci Aging Knowledge Environ. 2003;2003:RE5.  
3. Sen CK. The general case for redox control of wound repair. Wound Repair Regen. 
2003;11:431-438.  
4. Davies KJ, Quintanilha AT, Brooks GA, Packer L. Free radicals and tissue damage 
produced by exercise. Biochem Biophys Res Commun. 1982;107:1198-1205.  
5. Camici GG, Shi Y, Cosentino F, Francia P, Luscher TF. Anti-aging medicine: 
molecular basis for endothelial cell-targeted strategies - a mini-review. Gerontology. 
2011;57:101-108.  
6. Paradies G, Petrosillo G, Paradies V, Ruggiero FM. Role of cardiolipin peroxidation 
and Ca2+ in mitochondrial dysfunction and disease. Cell Calcium. 2009;45:643-650.  
7. Schriner SE, Linford NJ, Martin GM, Treuting P, Oqbum CE, Emond M, Coskun 
PE, Ladiges W, Wolf N, Van Remmen H, Wallace DC, Rabinovitch PS. Extension of 
murine life span by overexpression of catalase targeted to mitochondria. Science. 
2005;308:1909-1911.  
8. Fassett RG, Coombes JS. Astaxanthin: a potential therapeutic agent in 
cardiovascular disease. Mar Drugs. 2011;9:447-465.  
9. Timmers S, Hesselink MK, Schrauwen P. Therapeutic potential of resveratrol in 




10. Ramig LO, Gray S, Baker K, Corbin-Lewis K, Buder E, Luschei E, Coon H, Smith 
M. The aging voice: a review, treatment data and familial and genetic perspectives. 
Folia Phoniatr Logop. 2001;53:252-265.  
11. Sato K, Hirano M. Age-related changes of elastic fibers in the superficial layer of 
the lamina propria of vocal folds. Ann Otol Rhinol Laryngol. 1997;106:44-48.  
12. Hammond TH, Gray SD, Butler J, Zhou R, Hammond E. Age- and gender-related 
elastin distribution changes in human vocal folds. Otolaryngol Head Neck Surg. 
1998;119:314-322.  
13. Sato K, Hirano M, Nakashima T. Age-related changes of collagenous fibers in the 
human vocal fold mucosa. Ann Otol Rhinol Laryngol. 2002;111:15-20.  
14. Madruga de Melo EC, Lemos M, Aragao Ximenes Filho J, Sennes LU, Nascimento 
Saldiva PH, Tsuji DH. Distribution of collagen in the lamina propria of the human 
vocal fold. Laryngoscope. 2003;113:2187-2191.  
15. Ohno T, Hirano S, Rousseau B. Age-associated changes in the expression and 
deposition of vocal fold collagen and hyaluronan. Ann Otol Rhinol Laryngol. 
2009;118:735-741.  
16. Chen X, Thibeault SL. Characteristics of age-related changes in cultured human 
vocal fold fibroblasts. Laryngoscope. 2008;118:1700-1704.  
17. Higuera-Ciapara I, Felix-Valenzuela L, Goycoolea FM. Astaxanthin: a review of its 
chemistry and applications. Crit Rev Food Sci Nutr. 2006;46:185-196.  
18. Pashkow FJ, Watumull DG, Campbell CL. Astaxanthin: a novel potential 
treatment for oxidative stress and inflammation in cardiovascular disease. Am J 
Cardiol. 2008;101:58D-68D.  
22 
 
19. Wolf AM, Asoh S, Hiranuma H, Ohsawa I, Iio K, Satou A, Ishikura M, Ohta S. 
Astaxanthin protects mitochondrial redox state and functional integrity against 
oxidative stress. J Nutr Biochem. 2010;21:381-389.  
20. Gross GJ, Lockwood SF. Cardioprotection and myocardial salvage by a disodium 
disuccinate astaxanthin derivative (Cardax). Life Sci. 2004;75:215-224.  
21. Hama S, Takahashi K, Inai Y, Shiota K, Sakamoto R, Yamada A, Thuchiya H, 
Kanamura K, Yamashita E, Kogure K. Protective effects of topical application of a 
poorly soluble antioxidant astaxanthin liposomal formulation on 
ultraviolet-induced skin damage. J Pharm Sci. 2012;101:2909-2916.  
22. Mizuta M, Hirano S, Hiwatashi N, Tateya I, Kanemaru S, Nakamura T, Ito J. 
Effect of astaxanthin on vocal fold wound healing. Laryngoscope. 2013.  
23. Nakano M, Orimo N, Katagiri N, Tsubata M, Takahashi J, Van Chuyen N. 
Inhibitory effect of astraxanthin combined with Flavangenol on oxidative stress 
biomarkers in streptozotocin-induced diabetic rats. Int J Vitam Nutr Res. 
2008;78:175-182.  
24. Hirano S, Bless DM, del Rio AM, Connor NP, Ford CN. Therapeutic potential of 
growth factors for aging voice. Laryngoscope. 2004;114:2161-2167.  
25. Hirano S, Nagai H, Tateya I, Tateya T, Ford CN, Bless DM. Regeneration of aged 
vocal folds with basic fibroblast growth factor in a rat model: a preliminary report. 
Ann Otol Rhinol Laryngol. 2005;114:304-308.  
26. Ohno T, Yoo MJ, Swanson ER, Hirano S, Ossoff RH, Rousseau B. Regenerative 
effects of basic fibroblast growth factor on extracellular matrix production in aged 
rat vocal folds. Ann Otol Rhinol Laryngol. 2009;118:559-564.  
23 
 
27. Ohno T, Yoo MJ, Swanson ER, Hirano S, Ossoff RH, Rousseau B. Regeneration of 
aged rat vocal folds using hepatocyte growth factor therapy. Laryngoscope. 
2009;119:1424-1430.  
28. Hirano S, Tateya I, Kishimoto Y, Kanemaru S, Ito J. Clinical trial of regeneration of 






HPLC chromatograms of the standard astaxanthin sample and the extraction from 






(A) Representative examples of immunohistochemistry for 4-hydroxy-2-nonenal 
(4-HNE) in the lamina propria of vocal folds in the young group (a), the aged 
sham-treated group (b), and the aged astaxanthin (Ast)-treated group (c). 4-HNE 
appears green, while nuclei appear blue. Scale bar: 100 µm. (B) The immunopositive 
area for 4-HNE was measured in the lamina propria and presented as a value relative 
to the young group. The ratio of the 4-HNE-immunopositive area significantly increased 
in the two aged groups compared to the young group. No significant differences were 
observed in the 4-HNE-positive area between the aged sham-treated group and the 







A) Representative Alcian blue staining without hyaluronidase digestion (a, b, c) and 
with hyaluronidase digestion (d, e, f), and Elastica van Gieson staining (g, h, i) of the 
young group (a, d, g), the aged sham-treated group (b, e, h), and the aged astaxanthin 
(Ast)-treated group (c, f, i). The young group had abundant deposition of hyaluronic acid 
(HA) in the lamina propria. The sham-treated aged group showed a decrease of HA 
deposition, which was attenuated in the aged Ast-treated group. Elastica van Gieson 
staining showed excessive deposition of disorganized collagen in the lamina propria in 
both aged groups. Scale bar: 100 µm.  
B) The HA-stained area was measured and presented as a value relative to the young 
group. The deposition of HA in the LP was significantly reduced in the aged 
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sham-treated group compared to the young group. No significant difference was 
observed between the aged Ast-treated group and the young group (p=0.21). Bars 






mRNA expression ratios of several genes involved in the organization of vocal folds in 
the young group, the aged sham-treated group, and the aged astaxanthin (Ast)-treated 
group (Ast). The two aged groups showed significantly down-regulated mRNA 
expression of hyaluronic acid synthase (HAS)-1, HAS-2, HAS-3, procollagen types I and 
III, matrix metallopeptidase (MMP)-1a, and MMP-8 as compared to the young group. 
No significant differences were observed in the expression of these genes between the 
two aged groups. Bars represent the standard deviation. **: p < 0.01, *: p < 0.05, 






mRNA expression ratios of basic fibroblast growth factor (bFGF) and hepatocyte growth 
factor (HGF) in the young group, the aged sham-treated group, and the aged 
astaxanthin (Ast)-treated group. Although the aged sham-treated group showed a 
significantly down-regulated expression of bFGF and HGF as compared to the young 
group, there were no significant differences in the expression of these genes between the 
aged Ast-treated group and the young group. Bars represent the standard deviation. *: 
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